NanoVibronix, Inc. (NASDAQ:NAOV) saw its stock soar 70% after the medical technology firm announced it received a new U.S. patent, strengthening the intellectual property portfolio of its ENvue Medical subsidiary.
The U.S. Patent and Trademark Office granted Patent No. 12,409,105 B2 on September 9, 2025, titled “Insertion Device Positioning Guidance System and Method.” This patent protects NanoVibronix’s proprietary technology for guiding medical device insertion, such as feeding tubes, using electromagnetic positioning systems.
The company said the technology enhances real-time visualization and precision during medical procedures, reducing the likelihood of misplacement and related complications, allowing clinicians to operate more safely and efficiently.
“We believe this new patent is a significant milestone for us and highlights the strength of our innovation,” said Doron Besser, M.D., Chief Executive Officer of NanoVibronix. “We are continuing to build a robust and growing IP portfolio that not only protects our proprietary technology but also creates strong barriers to entry in our target markets.”
NanoVibronix focuses on non-invasive therapeutic systems and minimally invasive solutions. Its product lineup includes acoustic-based therapeutic devices like PainShield and UroShield, along with the ENvue Navigation Platform, FDA 510(k) cleared for adult feeding tube placement in the gastrointestinal tract.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.